title: Acute tumor lysis syndrome in poor-risk germ cell tumors: does it exist?
abstract: Acute tumor lysis syndrome (ATLS) is a well-known adverse event described after effective chemotherapy for extensive, highly proliferative, and chemosensitive tumors. While its occurrence with hematological malignancies is frequently described, there have been scattered case reports documenting ATLS in solid tumors. However, such events have not been reported in poor-risk germ cell tumors. We reviewed retrospectively 46 cases of such tumors treated in our department between 1988 and 1993 by aggressive cisplatin-based chemotherapy. All patients received systematically 6 l/24 h hydration according to the cisplatin- protocol administration. Blood chemistry data for potassium, phosphorus, calcium, alkaline reserve, uric acid, creatinine and lactate dehydrogenase were obtained before treatment and during the 7 days of the induction chemotherapy. No metabolic abnormalities suggestive of ATLS were observed. Nevertheless, 2 patients with bulky disease of the chest experienced early death from respiratory distress complicated by multiorgan failure. ATLS seems to be an unlikely event in poor-risk germ cell tumors and therefore special prophylactic therapy may be unnecessary.
authors.affiliation: Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
authors.forename: J
authors.initials: J
authors.lastname: Kattan
authors.forename: S
authors.initials: S
authors.lastname: Culine
authors.forename: T
authors.initials: T
authors.lastname: Tavakoli-Razavi
authors.forename: A
authors.initials: A
authors.lastname: Kramar
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000468:Alkalies / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002118:Calcium / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D018237:Germinoma / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000209:etiology*; D014527:Uric Acid / Q000097:blood; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000468:Alkalies; D001761:Bleomycin; D014527:Uric Acid; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D002945:Cisplatin; D002118:Calcium